PRESS RELEASES

Date Title and Summary View
Toggle Summary Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine
Regulus Therapeutics Appoints Hubert C. Chen, M.D., Vice President of Translational Medicine CARLSBAD, Calif., September 17, 2009 – Regulus Therapeutics Inc., a leading microRNA therapeutics company, today announced the appointment of Hubert C. Chen, M.D., as Vice President of Translational
View HTML
Toggle Summary Alnylam and Regulus Receive Notice of Allowance from United States Patent and Trademark Office for New Patent Covering microRNA Therapeutics
Manoharan Patent Covers Antagomirs, a Chemical Class of microRNA Inhibitors
View HTML
Toggle Summary Isis and Alnylam Launch Regulus Therapeutics, a Joint Venture to Discover, Develop, and Commercialize microRNA Therapeutics
By Targeting Gene Pathways, microRNA Therapeutics Represent a New Approach for the Treatment of a Broad Range of Human Disease
View HTML
Toggle Summary Releases Regulus Therapeutics Achieves Initial Milestone in its Inflammatory Diseases Collaboration with GlaxoSmithKline
First demonstration of a target-specific pharmacological effect for a microRNA antagonist in immune cells
View HTML
Toggle Summary Regulus Therapeutics Receives $20 Million in a Series A Equity Financing
The leading microRNA therapeutics company further strengthens balance sheet to advance programs towards the clinic
View HTML
Toggle Summary Regulus Therapeutics, Alnylam Pharmaceuticals, and Collaborators Publish First Ever In Vivo Efficacy Data for a microRNA Therapeutic in a Disease Model
New findings published in the journal Nature demonstrate therapeutic benefit of anti-microRNA-21 in an animal model of heart failure  **Companies to host conference call Monday, December 1, 2008 at 8:30 a.m. ET to discuss results
View HTML
Toggle Summary Regulus Therapeutics and Collaborators Discover Role of a microRNA in Tumor Angiogenesis
New Findings Published in the Journal Cancer Cell Highlight Role of miR-296 in Regulating Pathways of Angiogenesis and Demonstrate Potential New Applications of microRNA Therapeutics in Cancer
View HTML
Toggle Summary Isis Receives Notices of Allowance That Significantly Expand the Scope of Key RNA Therapeutic Patents
Allowances by U.S. Patent Office Enhance the “Crooke” Patent Estate by Adding Broad Claims That Cover RNA-Based Product Compositions and Methods of Treatment Expands Intellectual Property Position of Alnylam for RNAi Therapeutics and Regulus for microRNA Therapeutics
View HTML
Toggle Summary Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Appointment of Industry Renowned Leader Adds Extensive Experience to Board
View HTML
Toggle Summary Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors
Regulus Therapeutics and Collaborators Publish New Data on a Critical Role for miR-21 in Brain Tumors CAMBRIDGE, Mass. and CARLSBAD, Calif., August 19, 2008 – Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc.
View HTML